Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Rat (Rattus) Kallikrein 2 Antibodies:
anti-Human Kallikrein 2 Antibodies:
Go to our pre-filtered search.
Human Polyclonal Kallikrein 2 Primary Antibody for EIA, WB - ABIN358874
Haese, Vaisanen, Lilja, Kattan, Rittenhouse, Pettersson, Chan, Huland, Sokoll, Partin et al.: Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage ... in The Journal of urology 2005
Show all 2 references for ABIN358874
Human Polyclonal Kallikrein 2 Primary Antibody for WB - ABIN2777023
Hermans, Bressers, van der Korput, Dits, Jenster, Trapman: Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. in Cancer research 2008
Human Polyclonal Kallikrein 2 Primary Antibody for ELISA, IHC - ABIN4328019
Stephan, Xu, Brown, Breit, Michael, Nakamura, Diamandis, Meyer, Cammann, Jung: Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. in The Prostate 2006
Human Monoclonal Kallikrein 2 Primary Antibody for ICC, IHC (p) - ABIN1042614
Fisher, Nocera, Willis, Turner, Abdul Alim, Brown, Bourne, di SantAgnese, Messing, Lord, Frelinger: Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors. in The Prostate 2002
glycosylation changes the enzymatic activity of KLK2 in a drastically substrate-dependent manner.
The results indicated that W-hK2 (show HK2 Antibodies) had a defect in cellular trafficking due to its misfolding and that it activated the unfolded protein response, suggesting a mechanism to explain the association of the T allele with higher prostate cancer risk.
miR (show MLXIP Antibodies)-378 was predicted to target both KLK2 and KLK4 (show KLK4 Antibodies) and downregulated levels detected in prostate cancer patients.
The differential regulation of alternative transcripts (using KLK2, KLK3 (show KLKB1 Antibodies) and KLK4 (show KLK4 Antibodies) as models) by androgens and anti-androgens as an indicator of prostate cancers, was investigated.
Structure-function analyses of KLK2 establish the 99-loop as master regulator of its activity.
Predictions based on levels of four kallikrein (show KLK4 Antibodies) markers, including KLK2, in blood distinguish between pathologically insignificant and aggressive disease after radical prostatectomy with good accuracy.
Alteration of cellular junctions in benign prostatic hyperplasia could contribute to the presence of luminal epithelial secreted proteins prostate specific antigen (PSA (show KLK3 Antibodies))2 and and KLK2 in the stromal compartment.
we present the first evidence that KLK2 can also function as an androgen receptor (show AR Antibodies) modulator that may modulate cell growth after the development of castration-resistant prostate cancer
Associations observed in young, healthy men between the seminal plasma and serum concentrations of hK2 (show HK2 Antibodies) and PSA (show PLAG1 Antibodies) and several genetic variants in KLK2 and KLK3 (show KLKB1 Antibodies) could be useful to refine models of PSA (show PLAG1 Antibodies) cutoff values in prostate cancer testing.
Genetic variants at ATF7IP (show ATF7IP Antibodies) and KLK2 contribute to the variance of %fPSA.
This gene encodes a member of the grandular kallikrein protein family. Kallikreins are a subgroup of serine proteases that are clustered on chromosome 19. Members of this family are involved in a diverse array of biological functions. The protein encoded by this gene is a highly active trypsin-like serine protease that selectively cleaves at arginine residues. This protein is primarily expressed in prostatic tissue and is responsible for cleaving pro-prostate-specific antigen into its enzymatically active form. This gene is highly expressed in prostate tumor cells and may be a prognostic maker for prostate cancer risk. Alternate splicing results in both coding and non-coding transcript variants.
kallikrein 2, prostatic
, S2 kallikrein
, esterase 1
, glandular kallikrein-2
, Kallikrein 1 renal/pancreas/salivary
, kallikrein 5
, glandular kallikrein 2
, glandular kallikrein-1
, tissue kallikrein-2